Laboratory Equipment Market Size & Share 2026-2035

Laboratory Equipment Market Size

The global laboratory equipment market was valued at USD 23.9 billion in 2025 and is projected to advance from USD 25.2 billion in 2026 to USD 42.3 billion by 2035, reflecting a 5.9% CAGR. Demand is anchored in instruments and workflow systems that convert scientific activity into reproducible analytical, diagnostic, and process-development results. Analytical instruments accounted for USD 10.9 billion, or 45.7%, of 2025 revenue, reflecting their central role in regulated measurement and quality-control workflows.

Biopharma investment enlarges the addressable installed base for precision instruments rather than merely raising consumables demand. Sustained pharmaceutical and biotechnology funding and large-scale R&D expenditure continue to increase the number and complexity of programs that require validated analytical procedures, sample preparation, and data management. Laboratory automation reinforces that demand by shifting purchasing decisions from isolated devices toward interoperable workflows. Peer-reviewed research identifies robotics, artificial intelligence, connected sensors, and predictive-maintenance capabilities as core elements of total laboratory automation ^{[1]PMC / National Library of Medicine, Pioneering Trends in Total Laboratory Automation, pmc.ncbi.nlm.nih.gov}.

Growth will not be uniform across buyer types. Large pharmaceutical, clinical, and research networks can justify integrated systems through utilization and standardization; smaller laboratories face a more constrained investment case. The resulting market supports both premium, service-intensive direct channels and faster-growing digital procurement for standardized instruments and accessories.

The market covers analytical instruments, laboratory instruments, and other equipment; manual, semi-automatic, and automatic platforms; medical and clinical, pharmaceutical and biotechnology, food and beverage, chemical and material, academic, and other laboratory applications. It also encompasses healthcare, food and beverages, pharmaceuticals, academic and research institutions, chemicals, and other end-use industries, supplied through online and offline channels.

Key Drivers

Rising pharmaceutical and biotechnology R&D expands demand for instruments that can support development, release, stability, and quality-control work. Greater funding does not translate automatically into equipment purchases; it raises demand most directly when research programs move into regulated, data-intensive workflows requiring validated methods and reliable sample handling. The sustained scale of pharmaceutical and biotechnology R&D activity supports a durable pipeline of such work.

Automation, AI-enabled laboratory operations, connected equipment, and cloud-enabled data handling address a different constraint: the difficulty of scaling test volumes without proportionately expanding manual handling. Total laboratory automation research identifies real-time monitoring, automated data capture, proactive alerts, predictive maintenance, and troubleshooting as practical advantages of connected laboratory environments . These capabilities increase the value of instruments that integrate with scheduling, tracking, and laboratory-information workflows.

Chronic disease burden sustains demand from diagnostics and disease-monitoring laboratories. Cardiovascular diseases caused at least 19 million noncommunicable-disease deaths in 2021, while cancer, chronic respiratory disease, and diabetes accounted for substantial additional mortality ^{[2]World Health Organization, Noncommunicable diseases, who.int}. The commercial effect is not limited to diagnostic volume: it also supports investment in analytical methods used to develop, validate, and monitor therapies.

The estimated impacts are directional, non-additive scenario contributions derived from the approved 5.9% market forecast. They indicate the relative importance and timing of each force rather than measured independent additions to CAGR.

Key Restraints

Capital intensity limits the pace at which smaller laboratories can modernize. Specialist laboratory sources note that mass spectrometers, sequencers, bioreactors, and biosafety laboratory buildouts can require investment beyond the reach of many early-stage firms ^{[3]Tech Collective SEA, The rise of shared wet labs: lowering barriers for biotech startups, techcollectivesea.com}. This shifts purchasing toward shared laboratories, contract analytical services, leasing, phased automation, and instruments with a clearer utilization case. Suppliers that can lower installation, qualification, and service burdens are therefore better positioned to convert constrained buyers.

Compliance can lengthen equipment adoption cycles, particularly where systems support regulated medical-device, diagnostic, or pharmaceutical workflows. The U.S. Quality Management System Regulation final rule incorporated ISO 13485:2016 by reference, requiring manufacturers to adapt documentation and quality-system practices ^{[4]U.S. Government Publishing Office, Medical Devices; Quality System Regulation Amendments, govinfo.gov}. At the laboratory level, qualification and validation work commonly spans installation, operational, and performance stages ^{[5]Kneat, Equipment validation in the pharmaceutical industry, kneat.com}. The constraint is consequential because a technically capable instrument may still be delayed if its software controls, documentation, or auditability do not fit the buyer's validation requirements.

These estimated drags are non-additive directional assessments within the approved forecast. Their significance lies in how they redistribute demand toward service-supported procurement, modular upgrades, and equipment with stronger validation documentation.

Digitization changes the competitive basis further. A connected system can reduce manual intervention and support predictive maintenance, but it also broadens the validation perimeter to software, data integrity, and integration. Vendors that combine automation with credible documentation and local technical support can convert compliance from a sales obstacle into a differentiator.

Laboratory Equipment Market Segment Analysis

Equipment Type

Analytical instruments are projected to grow from USD 10.9 billion in 2025 to USD 19.0 billion by 2035 at a 5.8% CAGR. Spectrometers, including UV-Vis, IR, NMR, and mass spectrometers; chromatography equipment, including HPLC and GC; optical and electron microscopes; pH and conductivity meters; and balances and weighing equipment serve different points in the measurement chain. Their leadership reflects the need for defensible analytical results in development and quality control. ICH Q14 specifically addresses analytical-procedure development for commercial drug substances and products and identifies liquid chromatography-mass spectrometry among relevant methodologies ^{[6]International Council for Harmonisation, ICH Q14 Guideline: Analytical Procedure Development, database.ich.org}.

Laboratory instruments are forecast to expand from USD 7.8 billion to USD 14.4 billion at a 6.4% CAGR, outpacing the analytical category. Incubators and ovens, centrifuges, water-purification systems, autoclaves and sterilizers, and refrigerators and freezers are often bought as enabling infrastructure for higher sample volumes and more tightly controlled workflows. The other-equipment category is expected to rise from USD 5.2 billion to USD 8.9 billion at a 5.6% CAGR.

Automation Level

Manual systems remain relevant where test volumes, budgets, or methods do not justify automation. Semi-automatic platforms offer an intermediate route for laboratories standardizing repeatable steps. Automatic systems are gaining strategic importance where throughput, repeatability, traceability, and labor availability are binding constraints. Automation's value is strongest when it removes handoffs across an end-to-end workflow rather than automating a single isolated task .

Application and End-Use Industry. Medical and clinical laboratories prioritize reproducibility, turnaround time, and integration with diagnostic workflows. Pharmaceutical and biotechnology laboratories emphasize method development, molecular characterization, validation, and scale-up support. Food and beverage testing, chemical and material testing, and academic and educational laboratories require different balances of precision, throughput, method flexibility, and capital affordability. These applications map into healthcare, food and beverages, pharmaceuticals, academic and research institutions, chemicals, and other industries, creating demand for both broad portfolios and focused specialist instruments.

Distribution Channel

Offline distribution held USD 16.4 billion, or 68.5%, of market revenue in 2025 and is projected to reach USD 27.5 billion by 2035 at a 5.3% CAGR. Complex systems frequently require installation, calibration, qualification support, training, and field service, making local technical capability material to the purchase decision. Online sales are forecast to grow from USD 7.4 billion to USD 14.8 billion at a 7.2% CAGR, aided by more standardized purchases and repeat procurement. The channel mix therefore separates equipment that demands lifecycle support from products that can be specified and replenished digitally.

Online growth should not be interpreted as a broad substitution for technical distribution. It is most applicable where buyers can standardize specifications and acceptance criteria. Offline channels remain structurally important for chromatography, mass spectrometry, automation platforms, and other systems whose uptime and compliance depend on installation quality and local support.

Laboratory Equipment Market Regional Analysis

North America

North America was the largest regional market at USD 8.01 billion in 2025 and is projected to reach USD 13.58 billion by 2035 at a 5.5% CAGR. The U.S. represented USD 5.55 billion and 69.3% of the regional market in 2025, while Canada accounted for USD 2.46 billion. The region's large installed base of biopharma, diagnostics, and research laboratories supports demand for digitally connected and compliance-ready equipment, alongside replacement and workflow-upgrade purchases.

Europe

Europe is projected to expand from USD 5.70 billion in 2025 to USD 9.94 billion in 2035 at a 5.8% CAGR. Germany is expected to grow at 6.3%, while the UK, France, Spain, and Italy remain important national markets. The European regulatory environment creates a specific equipment requirement: manufacturers and laboratories must address traceability, clinical evidence, post-market oversight, and documentation. The European Commission identifies MDR and IVDR as the governing frameworks for medical devices and in vitro diagnostic devices ^{[7]European Commission, Medical devices: new regulations, health.ec.europa.eu}. EUDAMED-related requirements can make digital tracking and auditable records more commercially relevant for applicable device and diagnostic workflows.

Sustainability is an additional procurement consideration in Europe. The Corporate Sustainability Reporting Directive establishes sustainability-reporting requirements, while life-sciences guidance links supply-chain transparency and energy-use reporting to biotechnology organizations ^{[8]EUR-Lex, Directive (EU) 2022/2464 on corporate sustainability reporting, eur-lex.europa.eu}. This does not make a particular product mandatory, but it can favor equipment with measurable energy-management attributes, including variable-air-volume fume hoods and energy-efficient ultra-low-temperature freezers ^{[9]Scientific Labs, Energy efficiency in laboratories, scientificlabs.com}.

Asia Pacific

Asia Pacific is forecast to grow from USD 6.55 billion in 2025 to USD 12.17 billion in 2035 at a 6.4% CAGR, making it the fastest-growing major region. China is projected to record a 7.5% CAGR, and the region also includes Japan, India, Australia, and South Korea. ADC manufacturing investments in India and China illustrate the transition toward more complex biopharmaceutical production and development capacity, which increases the need for characterization, controlled processing, and automation infrastructure. In India, approximately 18,000 new clinical trials were registered in 2024, 50% more than in the prior year, supported by population diversity and established drug-manufacturing infrastructure. That expansion supports demand for scalable sample handling, analytical instruments, and temperature-controlled storage without assuming a fixed cycle-time improvement from automation.

Latin America

Latin America is expected to rise from USD 2.18 billion in 2025 to USD 4.04 billion at a 6.4% CAGR. Brazil, projected to grow at 7.1%, is a focal market alongside Mexico and Argentina.

Middle East and Africa

Middle East and Africa is forecast to grow from USD 1.44 billion to USD 2.57 billion at a 6.0% CAGR, with South Africa, Saudi Arabia, and the UAE forming the core country set. The UAE is projected to expand at 6.8%. In these regions, affordability, distributor capability, training, and service availability will be as material as instrument performance when laboratories expand capacity.

The strongest regional strategy is therefore not a uniform product rollout. Mature markets reward validated workflows, digital records, and lifecycle support, whereas faster-growing markets require scalable configurations, local service, and purchasing models that reduce upfront barriers. Suppliers that adapt the channel and service model to these differences can capture growth without relying solely on premium instrument sales.

Laboratory Equipment Market Share & Competitive Landscape

The top five companies - Thermo Fisher Scientific, Agilent Technologies, Bruker Corporation, Danaher Corporation, and PerkinElmer/Revvity - collectively accounted for approximately 40% of the market in 2025. Thermo Fisher Scientific led with an estimated 12% share. Its portfolio spans chromatography and mass spectrometry, electron microscopy, clinical diagnostics, laboratory automation, digital workflows, and data analytics, supporting a broad installed-base strategy across research and applied laboratories.

Agilent Technologies competes through analytical platforms and workflow-oriented diagnostics offerings. Its Dako Omnis expansion illustrates a focus on pathology-laboratory throughput, case-based processing, shared reagents, and reduced handling requirements. Revvity, formerly PerkinElmer, maintains relevance in life-sciences, applied, industrial, and environmental applications through imaging, detection, spectroscopy, chromatography, and related analysis technologies. GEA occupies a more specialized position with laboratory homogenizers for nanoparticles, nanodispersions, nanoemulsions, and cell disruption, supported by scale-up from laboratory testing to industrial production.

The competitive field also includes 3M, Abbott Laboratories, Atom Scientific Industries, Becton Dickinson, Labman Scientific Instruments, Roche, Sartorius, Siemens Healthineers, and Waters Corporation. Differentiation depends on the fit between instrument performance and the buyer's full operating environment: method validation, automation compatibility, software integration, application support, field service, and local distribution. This makes portfolio breadth valuable, but it does not eliminate opportunities for specialized suppliers with demonstrable workflow expertise.

Recent Industry Developments

• In August 2025, Agilent Technologies introduced the Dako Omnis 110, 165, and 165 Duo for pathology laboratories. The models support differing immunohistochemistry and in situ hybridization throughput needs and incorporate shared reagents with direct connections for de-ionized water and non-hazardous waste.
• In January 2025, Becton Dickinson and Biosero announced a framework collaboration to enable robotic-arm integration with BD flow cytometers for drug-discovery and development workflows. The partners planned compatible instrument and automation software intended to facilitate high-throughput, unattended multiwell-plate handling.
• In January 2025, Waters Corporation launched TGA Smart-Seal Pans for benchtop analysis of atmosphere-sensitive materials. The company stated that eliminating the need for a glovebox can reduce thermogravimetric-analysis system cost and footprint by up to 50% in applicable use cases.
• In February 2024, Bruker launched the BEAM FT-NIR spectrometer for in-process solid-sample control. The platform combines laboratory-grade precision with compact installation, dual-lamp operation, and integration options for pipelines, hoppers, and conveyor systems.